- Home
- ANIP vs KURA Comparison
ANIP vs KURA Comparison
Compare ANIP & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANIP
- KURA
- Stock Information
- Founded
- ANIP 2001
- KURA 2014
- Country
- ANIP United States
- KURA United States
- Employees
- ANIP N/A
- KURA N/A
- Industry
- ANIP Biotechnology: Pharmaceutical Preparations
- KURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ANIP Health Care
- KURA Health Care
- Exchange
- ANIP Nasdaq
- KURA Nasdaq
- Market Cap
- ANIP 1.3B
- KURA 1.3B
- IPO Year
- ANIP N/A
- KURA N/A
- Fundamental
- Price
- ANIP $56.58
- KURA $15.92
- Analyst Decision
- ANIP Buy
- KURA Strong Buy
- Analyst Count
- ANIP 6
- KURA 7
- Target Price
- ANIP $76.80
- KURA $29.83
- AVG Volume (30 Days)
- ANIP 278.1K
- KURA 821.5K
- Earning Date
- ANIP 11-08-2024
- KURA 11-07-2024
- Dividend Yield
- ANIP N/A
- KURA N/A
- EPS Growth
- ANIP N/A
- KURA N/A
- EPS
- ANIP N/A
- KURA N/A
- Revenue
- ANIP $555,456,000.00
- KURA N/A
- Revenue This Year
- ANIP $23.69
- KURA N/A
- Revenue Next Year
- ANIP $18.95
- KURA N/A
- P/E Ratio
- ANIP N/A
- KURA N/A
- Revenue Growth
- ANIP 23.60
- KURA N/A
- 52 Week Low
- ANIP $48.20
- KURA $9.06
- 52 Week High
- ANIP $70.81
- KURA $24.17
- Technical
- Relative Strength Index (RSI)
- ANIP 42.32
- KURA 34.68
- Support Level
- ANIP $57.80
- KURA $16.55
- Resistance Level
- ANIP $63.23
- KURA $19.73
- Average True Range (ATR)
- ANIP 2.43
- KURA 0.98
- MACD
- ANIP -0.05
- KURA -0.05
- Stochastic Oscillator
- ANIP 13.41
- KURA 8.86
About ANIP ANI Pharmaceuticals Inc.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.